Merck shells out $10 billion for Verona in bid to diversify past Keytruda - Reuters

Merck shells out $10 billion for Verona in bid to diversify past Keytruda Reuters
Merck shells out $10 billion for London-based lung remedy agency Verona CNBC
Merck spends $10 billion for Verona, getting access to its COPD medicine The Hill
Merck confirms $10B buyout of Verona Pharma (MRK:NYSE) Looking for Alpha
Merck to Purchase Verona Pharma, Increasing its Portfolio to Embody Ohtuvayre® (ensifentrine), a First-In-Class COPD Upkeep Therapy for Adults and Anticipated to Drive Progress into the Subsequent Decade Enterprise Wire